Key result
Chronic use of loop diuretics was significantly associated with a worse prognosis (HR 1.28), whereas the triple combination of RAAS inhibitors, MRAs, and β-blockers was associated with better prognosis when combined with low-dose loop diuretics.
Why the study?
Does the use of loop diuretics, and the addition of RAAS inhibitors and beta-blockers, affect prognosis in patients with symptomatic chronic heart failure?
Cohort (n=4,134)
Yes
Does the use of loop diuretics, and the addition of RAAS inhibitors and beta-blockers, affect prognosis in patients with symptomatic chronic heart failure?
Hazard Ratio: 1.28 (95% CI 1.17–1.39)
p-value: p=<0.001
Chronic loop diuretic use is associated with worse prognosis in heart failure in a dose-dependent manner, but this risk may be mitigated by combining low-dose loop diuretics with triple neurohormonal blockade (RAAS inhibitor, MRA, and beta-blocker).
No takes yet. Share an insight, caveat, or question.
May warrant cautious loop diuretic dosing in HF; leaves open whether triple blockade mitigates risk in trials.
Miura et al. (2016) conducted a cohort in Chronic Heart Failure (Stage C/D) (n=4,134). Loop diuretics vs. No loop diuretics was evaluated on Composite of all-cause death, heart failure admission, acute myocardial infarction, and stroke (HR 1.28, 95% CI 1.17-1.39, p=<0.001). Chronic use of loop diuretics was significantly associated with a worse prognosis (HR 1.28), whereas the triple combination of RAAS inhibitors, MRAs, and β-blockers was associated with better prognosis when combined with low-dose loop diuretics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: